Analystreport

Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating.

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report